Aclaris Therapeutics, Inc. (ACRS) Financial Statements (2025 and earlier)

Company Profile

Business Address 701 LEE ROAD
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:181,900229,800225,70054,10075,015167,972
Cash and cash equivalent39,87845,27727,34922,063  
Short-term investments79,228172,294164,06532,06839,078110,953
Other undisclosed cash, cash equivalents, and short-term investments62,79412,22934,286(31)35,93757,019
Receivables2984846237727044,861
Inventory, net of allowances, customer advances and progress billings      791
Inventory      791
Disposal group, including discontinued operation     4,966 
Other undisclosed current assets(53,342)1,266(21,291)2,6213,1185,875
Total current assets:128,856231,550205,03257,49383,803179,499
Noncurrent Assets
Property, plant and equipment1,6201,0991,3351,6542,4704,280
Long-term investments and receivables62,77112,24234,242   
Long-term investments62,77112,24234,242   
Intangible assets, net (including goodwill) 2696,9737,0487,1237,19991,455
Goodwill      18,504
Intangible assets, net (excluding goodwill) 2696,9737,0487,1237,19972,951
Other noncurrent assets3,8892,7323,5544,5144,825332
Total noncurrent assets:68,54923,04646,17913,29114,49496,067
TOTAL ASSETS:197,405254,596251,21170,78498,297275,566
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28,32419,05220,03611,16017,63827,342
Accounts payable8,87810,3519,9855,2549,91714,755
Accrued liabilities19,4468,70110,0515,9067,72112,587
Deferred revenue     
Disposal group, including discontinued operation 2,2022,2022,2023,1114,157 
Other liabilities  693603637 
Other undisclosed current liabilities 426684    
Total current liabilities:30,95221,93822,93114,87422,43227,342
Noncurrent Liabilities
Long-term debt and lease obligation:    2,894  
Liabilities, other than long-term debt9,27435,03730,9397,6075,9533,186
Deferred revenue     
Deferred tax liabilities, net549
Deferred income tax liabilities  367367367549
Other liabilities3,0741,5702,1723,1793,7361,703
Operating lease, liability    2,894 
Business combination, contingent consideration, liability6,20033,10028,4004,0611,668934
Other undisclosed noncurrent liabilities    7,759 29,914
Total noncurrent liabilities:9,27435,03730,93918,2605,95333,100
Total liabilities:40,22656,97553,87033,13428,38560,442
Equity
Equity, attributable to parent157,179197,621197,34137,65069,912215,124
Common stock111   
Additional paid in capital928,080880,832792,971542,286523,505507,366
Accumulated other comprehensive income (loss)(106)(897)(224)(94)(66)(69)
Accumulated deficit(770,796)(682,315)(595,407)(504,542)(453,527)(292,173)
Total equity:157,179197,621197,34137,65069,912215,124
TOTAL LIABILITIES AND EQUITY:197,405254,596251,21170,78498,297275,566

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues31,24929,7526,7616,4824,22710,091
Cost of revenue(3,423)(4,023)(4,713)(5,133)(4,055)(6,850)
Gross profit:27,82625,7292,0481,3491723,241
Operating expenses(137,425)(102,946)(67,432)(52,261)(111,230)(138,655)
Other undisclosed operating income (loss)12,242(12,637)(24,339)   
Operating loss:(97,357)(89,854)(89,723)(50,912)(111,058)(135,414)
Nonoperating income (expense)8,5092,946(1,142)(424)(2,484)2,676
Investment income, nonoperating      
Other nonoperating income (expense) 8,5092,946(1,142)(424)(2,484)2,676
Interest and debt expense   (752)(5)(87) 
Other undisclosed income from continuing operations before equity method investments, income taxes    144  
Loss from continuing operations before equity method investments, income taxes:(88,848)(86,908)(91,617)(51,197)(113,629)(132,738)
Other undisclosed income (loss) from continuing operations before income taxes   752(139)(47,725) 
Loss from continuing operations before income taxes:(88,848)(86,908)(90,865)(51,336)(161,354)(132,738)
Income tax benefit 367  182  
Loss from continuing operations:(88,481)(86,908)(90,865)(51,154)(161,354)(132,738)
Loss before gain (loss) on sale of properties:(90,865)(51,015)(161,354)(132,738)
Income from discontinued operations    139  
Net loss available to common stockholders, diluted:(88,481)(86,908)(90,865)(51,015)(161,354)(132,738)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(88,481)(86,908)(90,865)(51,015)(161,354)(132,738)
Other comprehensive income (loss)791(673)(130)(28)3177
Comprehensive loss, net of tax, attributable to parent:(87,690)(87,581)(90,995)(51,043)(161,351)(132,561)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: